NEW YORK (Reuters) - Teva Pharmaceutical Industries Ltd plans to acquire specialty drugmaker Cephalon for $81.50 a share, topping an unsolicited bid by Canada's Valeant Pharmaceuticals International Inc .
Teva said the deal was worth about $6.8 billion on an enterprise basis. The deal is worth about $6.2 billion, based on the number of CEPHALON (CEPH.NQ)shares outstanding, according to Thomson Reuters data.
(Reporting by Lewis Krauskopf; Editing by Lisa Von Ahn)
